# Filing Detail

Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001493152-26-014691
Filing Date
2026-04-01
Accepted
2026-04-01 16:50:49
Documents
9

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 424B3 | form424b3.htm | 424B3 | 2175708
2 | GRAPHIC | form424b3_001.jpg | GRAPHIC | 4839
3 | GRAPHIC | ex10-69_001.jpg | GRAPHIC | 251513
4 | GRAPHIC | ex10-69_002.jpg | GRAPHIC | 616554
5 | GRAPHIC | ex10-69_003.jpg | GRAPHIC | 232249
6 | GRAPHIC | ex10-69_004.jpg | GRAPHIC | 361968
7 | GRAPHIC | ex10-69_005.jpg | GRAPHIC | 520636
8 | GRAPHIC | form10-k_001.jpg | GRAPHIC | 32378
9 | GRAPHIC | form10-k_002.jpg | GRAPHIC | 31387
| Complete submission text file | 0001493152-26-014691.txt |  | 5003047

Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-286662 | Film No.: 26829122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)